321 related articles for article (PubMed ID: 27653003)
1. Bisphosphonates and atypical femoral fractures.
Adler RA
Curr Opin Endocrinol Diabetes Obes; 2016 Dec; 23(6):430-434. PubMed ID: 27653003
[TBL] [Abstract][Full Text] [Related]
2. Current Understanding of Epidemiology, Pathophysiology, and Management of Atypical Femur Fractures.
Starr J; Tay YKD; Shane E
Curr Osteoporos Rep; 2018 Aug; 16(4):519-529. PubMed ID: 29951870
[TBL] [Abstract][Full Text] [Related]
3. MANAGEMENT OF ENDOCRINE DISEASE: Atypical femoral fractures: risks and benefits of long-term treatment of osteoporosis with anti-resorptive therapy.
Adler RA
Eur J Endocrinol; 2018 Mar; 178(3):R81-R87. PubMed ID: 29339529
[TBL] [Abstract][Full Text] [Related]
4. A proposal for an atypical femur fracture treatment and prevention clinical practice guideline.
Dell R; Greene D
Osteoporos Int; 2018 Jun; 29(6):1277-1283. PubMed ID: 29675745
[TBL] [Abstract][Full Text] [Related]
5. Trends in the incidence of atypical femoral fractures and bisphosphonate therapy.
Clout A; Narayanasamy N; Harris I
J Orthop Surg (Hong Kong); 2016 Apr; 24(1):36-40. PubMed ID: 27122510
[TBL] [Abstract][Full Text] [Related]
6. Bisphosphonates and the risk of atypical femur fractures.
Black DM; Condra K; Adams AL; Eastell R
Bone; 2022 Mar; 156():116297. PubMed ID: 34920168
[TBL] [Abstract][Full Text] [Related]
7. Medical Management of Patients After Atypical Femur Fractures: a Systematic Review and Recommendations From the European Calcified Tissue Society.
van de Laarschot DM; McKenna MJ; Abrahamsen B; Langdahl B; Cohen-Solal M; Guañabens N; Eastell R; Ralston SH; Zillikens MC
J Clin Endocrinol Metab; 2020 May; 105(5):1682-99. PubMed ID: 31867670
[TBL] [Abstract][Full Text] [Related]
8. Trabecular Bone Score and Hip Structural Analysis in Patients With Atypical Femur Fractures.
Buitendijk SKC; van de Laarschot DM; Smits AAA; Koromani F; Rivadeneira F; Beck TJ; Zillikens MC
J Clin Densitom; 2019; 22(2):257-265. PubMed ID: 29661684
[TBL] [Abstract][Full Text] [Related]
9. Incidence, risk factors, and fracture healing of atypical femoral fractures: a multicenter case-control study.
Lim SJ; Yeo I; Yoon PW; Yoo JJ; Rhyu KH; Han SB; Lee WS; Song JH; Min BW; Park YS
Osteoporos Int; 2018 Nov; 29(11):2427-2435. PubMed ID: 30039251
[TBL] [Abstract][Full Text] [Related]
10. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research.
Shane E; Burr D; Abrahamsen B; Adler RA; Brown TD; Cheung AM; Cosman F; Curtis JR; Dell R; Dempster DW; Ebeling PR; Einhorn TA; Genant HK; Geusens P; Klaushofer K; Lane JM; McKiernan F; McKinney R; Ng A; Nieves J; O'Keefe R; Papapoulos S; Howe TS; van der Meulen MC; Weinstein RS; Whyte MP
J Bone Miner Res; 2014 Jan; 29(1):1-23. PubMed ID: 23712442
[TBL] [Abstract][Full Text] [Related]
11. Differences in bone histomorphometry between White postmenopausal women with and without atypical femoral fracture after long-term bisphosphonate therapy.
Qiu S; Dhaliwal R; Divine G; Warner E; Rao SD
J Bone Miner Res; 2024 May; 39(4):417-424. PubMed ID: 38477744
[TBL] [Abstract][Full Text] [Related]
12. Incidence and medical management of bisphosphonate-associated atypical femoral fractures in a major trauma centre: a retrospective observational study.
Eisenstein N; Kasavkar G; Bhavsar D; Khan FS; Paskins Z
BMC Musculoskelet Disord; 2017 Jan; 18(1):29. PubMed ID: 28114975
[TBL] [Abstract][Full Text] [Related]
13. Clinical characteristics, densitometric parameters and outcomes of patients with atypical femoral fractures related to bisphosphonate treatment for osteoporosis.
Wong CH; Kan AKC; Tsoi KH; Chan SSY; Jiang NS; Loong CHN; Fong CHY; Wong JSH; Shea GKH; Cheung CL; Lee CH; Tan KCB; Woo YC; Lui DTW
Endocrine; 2024 Apr; 84(1):223-235. PubMed ID: 37985574
[TBL] [Abstract][Full Text] [Related]
14. Detection and management of atypical femur fractures.
Divan V; Rao SD; Dhaliwal R
Curr Opin Endocrinol Diabetes Obes; 2019 Dec; 26(6):283-290. PubMed ID: 31592780
[TBL] [Abstract][Full Text] [Related]
15. Bone cross-sectional geometry is not associated with atypical femoral fractures in Asian female chronic bisphosphonate users.
Chou AC; Ng AC; Png MA; Chua DT; Ng DC; Howe TS; Koh JS
Bone; 2015 Oct; 79():170-5. PubMed ID: 26067179
[TBL] [Abstract][Full Text] [Related]
16. Different surgical outcomes in a patient with bilateral atypical femoral fracture related to bisphosphonate use with or without teriparatide treatment.
Zhang HY; Weng HL; Li M; Zhang J
Osteoporos Int; 2019 Nov; 30(11):2349-2354. PubMed ID: 31428823
[TBL] [Abstract][Full Text] [Related]
17. Medication management after intramedullary nailing of atypical fractures.
Feron JM; Cambon-Binder A
Injury; 2017 Jun; 48 Suppl 1():S15-S17. PubMed ID: 28456365
[TBL] [Abstract][Full Text] [Related]
18. Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: a systematic review and meta-analysis.
Gedmintas L; Solomon DH; Kim SC
J Bone Miner Res; 2013 Aug; 28(8):1729-37. PubMed ID: 23408697
[TBL] [Abstract][Full Text] [Related]
19. Biomechanical mechanisms of atypical femoral fracture.
Ural A
J Mech Behav Biomed Mater; 2021 Dec; 124():104803. PubMed ID: 34479108
[TBL] [Abstract][Full Text] [Related]
20. Atypical Femoral Fractures : Three Cases And A Review Of Literature.
Van Lieshout M; Putzeys G; Goemaere S; Van Der Straeten C; Audenaert E
Acta Orthop Belg; 2017 Dec; 83(4):558-567. PubMed ID: 30423662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
